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Abstract
Purpose Gene expression (GE) profiling for breast cancer classification and prognostication has become increasingly used 
in clinical diagnostics. GE profiling requires a reasonable tumor cell percentage and high-quality RNA. As a consequence, 
a certain amount of samples drop out. If tumor characteristics are different between samples included and excluded from 
GE profiling, this can lead to bias. Therefore, we assessed whether patient and tumor characteristics differ between tumors 
suitable or unsuitable for generating GE profiles in breast cancer.
Methods In a consecutive cohort of 738 breast cancer patients who received neoadjuvant chemotherapy at the Netherlands 
Cancer Institute, GE profiling was performed. We compared tumor characteristics and treatment outcome between patients 
included and excluded from GE profiling. Results were validated in an independent cohort of 812 patients treated with 
primary surgery.
Results GE analysis could be performed in 53% of the samples. Patients with tumor GE profiles more often had high-grade 
tumors [odds ratio 2.57 (95%CI 1.77–3.72), p < 0.001] and were more often lymph node positive [odds ratio 1.50 (95%CI 
1.03–2.19), p = 0.035] compared to the group for which GE profiling was not possible. In the validation cohort, tumors 
suitable for gene expression analysis were more often high grade.
Conclusions In our gene expression studies, tumors suitable for GE profiling had more often an unfavorable prognostic pro-
file. Due to selection of samples with a high tumor percentage, we automatically select for tumors with specific features, i.e., 
tumors with a higher grade and lymph node involvement. It is important to be aware of this phenomenon when performing 
gene expression analysis in a research or clinical context.
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Introduction
DNA microarray analyses (e.g., tiling arrays, mRNA arrays, 
and direct sequencing of complementary DNA) have sig-
nificantly advanced our understanding of breast cancer. 
They showed that breast cancer is not a single disease with 
variable morphologic features, but a group of molecular dis-
tinct neoplasms [1]. Furthermore, in certain clinical settings 
it can help to determine whether or not adjuvant chemo-
therapy is justified [2].
Several assays, resulting in risk scores, have been devel-
oped and are partially commercially and partially clinically 
available. The 21-gene Recurrence Score (OncotypeDx 
assay, Genome Health inc, Redwood city, CA) [3], the 
Amsterdam 70-gene profile, commercially known as the 
Mammaprint (Agendia, Huntington Beach, CA) assay [4] 
and the Risk of Recurrence (ROR) score, derived from Pre-
dictor Analysis of Microarray 50 (PAM50) [5], are mostly 
used. Reliable results of the assays require a good qual-
ity tumor sample with high cellularity. To illustrate this, 
Elloumi et al. [6] revealed a systematic bias when too much 
normal tissue was present in a tumor sample. However, 
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tumor percentage is also dependent on tumor morphology. 
For example, a tumor with solid growth more easily reaches 
a high tumor percentage than a tumor with glandular or lob-
ular growth (a feature important for grade). Furthermore, 
the presence of sclerosis as well as stromal and inflamma-
tory cells can reduce the tumor cell percentage substantially. 
Another feature that influences the ability to perform gene 
expression analysis is the RNA quality. Pre-analytical fac-
tors such as time to fixation, fixation duration, and storage 
temperature have an impact on the RNA quality [7].
Summarizing the above, a high tumor percentage and 
good quality RNA are prerequisites for successful gene 
expression analysis. These requirements lead to the dropout 
of samples not fulfilling these criteria. As a higher histologi-
cal grade is associated with a higher tumor cellularity, gene 
expression analysis might be more successful in high-grade 
tumors. To assess if indeed clinico-pathological variables 
are associated with successful gene expression analysis, we 
compared clinical and tumor characteristics of tumors suit-
able and unsuitable for gene expression analysis in two large 
(neo) adjuvant-treated patient cohorts.
Materials and methods
Patient selection
Tissue samples of patients treated in the neoadjuvant setting 
for breast cancer were collected at the Netherlands Cancer 
Institute (NKI) between 2004 and 2012. For participation in 
the neoadjuvant program, the tumor diameter should exceed 
3 cm or axillary lymph node metastasis should be proven 
by fine-needle aspiration. Part of these patients participated 
in two ongoing clinical trials of which details have been 
described previously [8]. Both studies were approved by the 
ethical committee and informed consent for gene expres-
sion analysis was obtained for all included patients. At least 
two tumor biopsies were taken under ultrasound guidance, 
using a 14G core needle to assure sufficient tissue for both 
adequate diagnostics as well as for research purposes. To 
facilitate such analyses, at least one biopsy was snap frozen 
in liquid nitrogen and stored at − 80 degrees.
Pathology
Paraffin-embedded sections were all stained by a hematox-
ylin and eosin (H&E) stain and reviewed by a consultant 
breast pathologist (JW) for immunohistochemically assess-
ment and histological classification (including subtype and 
grade) on biopsy material (of which the details are described 
previously) [9]. In brief, samples were scored as positive for 
oestrogen receptor (ER) and progesterone receptor (PR) if at 
least 10% of the tumor cells showed nuclear staining. HER2 
(or ERBB2) was scored as positive when there was strong 
membranous staining in more than 30% of the tumor cells 
(3+) by immunohistochemistry or if chromosome in situ 
hybridization (CISH) revealed amplification. Percentage 
nuclear staining of tumor cells in Ki67 (MIB1) was scored 
as a marker for proliferation. Chemotherapy response was 
determined by pathological examination of resection speci-
mens. Pathological complete remission (pCR) was defined 
as the absence of invasive tumor in both the breast and axil-
lary lymph nodes after neoadjuvant chemotherapy.
Imaging data
For a subset of the patients, detailed imaging data were 
available. A dedicated breast radiologist (CL) assessed 
according to BIRADS lexicon [10] whether pre-treatment 
MRIs showed the tumor to be either mass-like, or non-mass 
like. For analysis purposes, these two categories were used. 
Metabolic activity was assessed using baseline 18F-fluoro-
deoxyglucose (FDG) positron emission tomography com-
bined with computed tomography (PET/CT) scans. FDG 
uptake was quantified using maximum standardized uptake 
values (SUVmax) measured with Osirix DICOM viewer 
(Pixmeo SARL, Geneva, Swiss).
Gene expression assay and tumor percentage
mRNA was isolated from the frozen material as described 
previously [9]. Briefly, a 5-micrometer section of the biopsy 
was H&E stained. A pathologist evaluated if the overall tis-
sue quality of the frozen biopsy was sufficient for further 
analysis (i.e., samples dropped out if the biopsy was too 
small, too fatty or in the absence of invasive tumor). The 
pathologist also estimated the tumor percentage and only 
the samples with a tumor percentage ≥ 50% were selected 
for microarray analysis. Gene expression analysis was 
only performed if the RNA integrity number ≥ 6.5 and the 
quantity ≥ 3 µg. Samples obtained between 2004 and 2010 
were analyzed using Illumina microarray analysis (WG6 v3 
microarray chips); RNAseq was performed on the samples 
from 2011 to 2012.
Validation cohort
As a validation, an independent cohort obtained from the 
microarRAy PrognoSTics in Breast cancER (RASTER) 
study was used. Study design is described before [11]. In 
short, 812 women were enrolled in 16 hospitals in The 
Netherlands after having given informed consent. Patients 
received surgery (mastectomy or breast conserving surgery) 
as primary treatment. Within 1 h after surgery, a tumor sam-
ple was procured at the pathology department of the partici-
pating hospitals and sent to Netherlands Cancer institute by 
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mail. After samples were received at the Netherlands Cancer 
Institute they were snap frozen at − 70 degrees. Pathologists 
analyzed paraffin-embedded tumor samples of the validation 
dataset at the pathology department of the participating hos-
pitals. Histological tumor grade according Elston and Ellis, 
ER status, PR status, and ERBB2 status were established 
by each hospital according to locally used methods [11]. 
Frozen sections of the tumor samples of the validation set 
were obtained and stained with H&E stain, and subsequently 
analyzed by an experienced breast pathologist. Eligible sam-
ples had to contain ≥ 50% tumor cells. Agendia Laboratories 
performed the microarray analysis using the Mammaprint 
(Agilent microarray, Santa Clara USA) [11].
Data analyses and statistics
The variables age, histologic subtype of tumor, grade, 
T-stage, N-stage, and response (pathological complete 
remission (pCR) of breast and axilla) were compared 
between samples suitable or unsuitable for gene expression 
analysis. The χ2 (Spearman) was used to compare dichot-
omized variables. We also assessed differences in clini-
cal characteristics for each exclusion criteria as described 
above, i.e., tissue quality of the frozen biopsy, tumor cell 
percentage, and RNA quantity as well as quality. Multivari-
ate logistic regression analysis was performed to assess the 
independent association of various clinical variables with 
the ability to perform GE analysis. Recurrence-free survival 
was assessed with Kaplan–Meier plots and the log rank test. 
A cox proportional hazard model was built to assess if the 
ability to perform GE analysis was independently associated 
with recurrence-free survival. The SPSS Package 23.0 was 
used for statistical analyses and p values (two-sided) < 0.05 
were considered statistically significant. This study was 
designed according to the Reporting recommendations for 
tumor MARKER prognostic studies (REMARK) guidelines 
[12].
For the validation dataset, the variables age, histologic 
type of tumor, subtype, histological grade, and T-stage were 
compared between tumor samples suitable or ineligible for 
gene expression analysis. Statistical analysis was performed 
as described above.
Results
Patient selection in cohort
A total of 738 breast cancer patients were treated in the 
NKI with neoadjuvant chemotherapy between 2004 and 
2012. From 665 patients, a frozen biopsy was available. 
Seventy-seven tissue samples were not processed because 
the biopsies were too small or too fatty, or did not contain 
invasive tumor. Of the remaining 587 tissue specimens, 
461 had a tumor percentage of more than 50%; 391 of 
these samples met the criteria for sufficient RNA quality 
and quantity, allowing gene expression analysis (53% of 
the total cohort). Figure 1 shows the sample selection flow 
diagram.
Association with clinical characteristics
Comparisons of baseline characteristics between the 
tumors for which a gene expression (GE) profile could 
be generated (GE+ ; n = 391) and the tumors for which 
this was not possible (GE−  ; n  =  347) are shown in 
Table 1. GE + tumors were more often high grade and 
had a higher SUV max value than GE− tumors. When we 
stratify for subtype, the effect of grade is still significant in 
the ER+HER2− and in the triple-negative subgroup (see 
Supplementary, Table 1). In the ER+HER2− subgroup, 
these samples also have a higher SUV max value. Multi-
variate analysis shows that a high tumor grade and posi-
tive lymph node status are independently associated with 
GE + tumors (Table 2).
Patients started with neoadjuvant 
chemotherapy inclusion criteria 
met (2004-2012)
n=738
Frozen biopsy 
available
n=665
Good quality 
frozen biopsy
n=587
TP≥ 50%
n=461
Gene expression 
data available
n=391
No frozen 
tissue available 
(n=73)
Biopsy too 
small, too fatty 
or contains only 
DCIS (n= 78)
TP<50% 
(n=126)
RIN value <6.5 
or RNA quantity 
<3 µg (n=70)
Fig. 1  Flow diagram of included patients. Flow diagram of included 
patients and in- and exclusion steps of the fresh frozen biopsies for 
gene expression studies. TP denotes tumor percentage, DCIS ductal 
carcinoma in situ, RIN RNA integrity number
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To investigate the influence of the various steps of sample 
selection for gene expression analysis in more detail, we 
compared the clinical variables between in- and excluded 
samples after each selection step (Table 3). Interestingly, in 
every selection step, we enrich for high-grade tumors: a high 
tumor grade is associated with larger biopsies, higher tumor 
percentage and high quality and quantity RNA. In addition, 
high quality and sufficient quantity of RNA is more often 
found in HER2+ tumors and node-positive tumors.
Association with treatment response and survival
Chemotherapy response was not significantly different 
between GE + and GE − tumors. However, we observed 
that tumors with high tissue quality of frozen biopsies more 
often achieved a pathological compete response (pCR) 
after treatment than samples with poor quality biopsies 
(p = 0.02; Table 3). We did not observe a significant differ-
ence in recurrence-free survival between samples included 
Table 1  Characteristics of 
patients with gene expression 
profiles versus patients without 
gene expression profiles
Due to rounding, some percentages do not count up to 100%. GE denoted gene expression, IDC invasive 
ductal carcinoma, ILC invasive lobular carcinoma, ER oestrogen receptor, HER2 ERBB2, SUV standard-
ized uptake value
Bold p-values denote p-values statitically significant at a 0.05 cut-off
No GE data avail-
able (n = 347)
GE data avail-
able (n = 391)
p value
Age  < 50 189 (55%) 237 (61%) 0.13
 > = 50 153 (45%) 153 (39%)
 Unknown 5 1
Histology  IDC 244 (87%) 291 (90%) 0.25
 ILC 38 (13%) 34 (10%)
 Unknown 65 66
Subtype  ER+, Her2− 182 (53%) 182 (47%) 0.25
 Her2+ 73 (21%) 96 (25%)
 Tripleneg 91 (26%) 113 (29%)
 Unknown 1 0
ER  ER neg 122 (35%) 149 (38%) 0.44
 ER pos 223 (65%) 242 (62%)
 Unknown 2 0
HER2  Her2 neg 272 (79%) 293 (75%) 0.26
 Her2 pos 73 (21%) 96 (25%)
 Unknown 2 2
Grade  Grade 1 & 2 184 (70%) 158 (48%) < 0.01
 Grade 3 80 (30%) 170 (52%)
 Unknown 83 63
T-stage  T1/T2 232 (68%) 270(70%) 0.65
 T3/T4 109 (32%) 118 (30%)
 Unknown 6 3
N-stage  Neg 104 (30%) 94 (24%) 0.06
 Pos 239 (70%) 294 (76%)
 Unknown 4 3
Response (breast and lymph node)  No pCR 270 (79%) 293 (75%) 0.22
 pCR 72 (21%) 97 (25%)
 Unknown 5 1
Ki-67  > 15% 103 (49%) 98 (49%) 0.95
 ≤ 15% 107 (51%) 103 (51%)
 Unknown 137 190
Mass (MRI)  Non-mass 47 (55%) 53 (55%) 0.94
 Mass 39 (45%) 43 (45%)
 Unknown 261 295
Maximal SUV-uptake mean (sd) 7.19 (4.55) 10.03 (6.79) 0.03
Unknown 259 294
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and excluded in gene expression analysis, although a trend 
was visible in triple-negative patients (Fig. 2). A cox pro-
portional hazard model did not indicate GE+ as a variable 
associated with survival (Supplementary, Table 2).
Results in the validation dataset
The RASTER data were used to validate our observations. 
This set includes 812 breast cancer patients enrolled between 
2004 and 2006 (see Methods). Because node positive patients 
were excluded in this study for clinical reasons and therefore 
a gene expression profile was not performed, we analyzed the 
samples of node-negative patients (n = 585, see Supplemen-
tary Fig. 1, for a flowchart). Therefore, we could not validate 
our association with nodal status in this set; however, most 
other clinical variables were available. Of these samples, 27% 
dropped out because of incorrect procedure or sample failure. 
Similar to the observations in the neoadjuvant cohort, gene 
expression profiling was more often possible in high-grade 
tumors (borderline significant; p = 0.05, Table 4).
Discussion
In this study, we showed that patients of whom gene expres-
sion data were obtained had more often high-grade tumors and 
lymph node metastasis, features associated with a worse prog-
nosis. It is important to acknowledge that, due to the selection 
of tumors with good quality samples and a high cellularity for 
gene expression studies, we select for a certain subgroup of 
tumors. Most likely, this selection bias is present in the majority 
of published gene expression studies for breast cancer.
Our findings are indeed in line with published literature. 
Cremoux et al. [13] studied (pre-) analytical steps in tis-
sue handling by comparing different institutes. As in our 
study, they found that tumors suitable for gene expression 
profiling were more often high grade and of ductal subtype. 
Mook et al. observed a 17% dropout and concluded that 
the rejected samples were obtained from slightly smaller 
tumors [14]. Also Goetz et al. observed that women without 
expression data had more often a small tumor [15]. Together 
with the results of our validation dataset, there is substantial 
evidence towards the selection of larger and more aggressive 
tumors for gene expression studies.
In a systematic literature search that we performed prior 
to this study, finally resulting in 110 articles, 39% of the 
studies were indistinct about exclusion criteria and associ-
ated dropout rates, indicating unawareness. The remaining 
61% did mention about exclusion criteria and numbers. 
These studies show a variety of dropout rates (1–83%, aver-
age 21%). Most gene expression profiles had been devel-
oped on frozen sample collections available at the biobank 
of the respective institute. These samples are a selection 
of relatively large and easily accessible tumors. Also, only 
samples that met the strict criteria of tumor RNA quality 
and quantity were used. Nowadays FFPE material from all 
laboratories (both biopsies and resection material), with 
very different protocols, can be measured by commercial 
available platforms, such as Mammaprint and OncotypeDx, 
and tumor percentage can be as low as 30% [16]. This is 
possible due to advances in the technique. However, we 
should be aware that such assays were originally not devel-
oped on samples with comparable characteristics, and vali-
dation on small samples with lower tumor cell percentage 
is warranted. In addition, also for research purposes, it is 
important to acknowledge that due to analytical require-
ments high-grade tumors might be overrepresented in GE 
datasets.
This study has some limitations. First, fresh frozen 
tumor samples were used. In general, it is more difficult 
to obtain fresh frozen material than FFPE tumor mate-
rial, resulting in a higher dropout rate. Second, this study 
was done on pre-treatment biopsies, which yield smaller 
quantities of tumor material than resection specimens. 
Third, this study was performed in the neoadjuvant setting, 
which results in the selection of locally advanced tumors. 
Consequently, we could not look at stage I or stage IV 
tumors. Strong points of our study are that samples were 
obtained from a consecutive cohort of neoadjuvant treated 
patients, and not on a highly selected clinical trial popula-
tion. Furthermore, we had an independent cohort for vali-
dation purposes that corroborated our findings. Although 
there were some differences in the way the samples were 
Table 2  Multivariate analyses of patient characteristics with gene 
expression profiles versus patients without gene expression profiles
An odds ratio above one means that gene expression analysis is more 
likely in this patient group. ER denoted oestrogen receptor, HER2 
ERBB2
Bold p-values denote p-values statitically significant at a 0.05 cut-off
Variable Frequency Odds ratio 95% CI p value
Age  < 50 339 1.00
 > = 50 245 0.91 0.64–1.28 0.58
ER  ER neg 218 1.00
 ER pos 366 1.19 0.81–1.74 0.38
HER2  Her2 neg 440 1.00
 Her2 pos 144 1.20 0.81–1.80 0.36
Grade  Grade 1 
& 2
336 1.00
 Grade 3 248 2.56 1.77–3.71 < 0.01
T-stage  T1/T2 408 1.00
 T3/T4 176 0.94 0.65–1.35 0.73
N-stage  Neg 163 1.00
 Pos 421 1.53 1.05–2.23 0.03
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collected (resections versus biopsies, mailed transport ver-
sus snap frozen), the validation cohort consisted of early 
stage breast cancer samples and had information on grade, 
enabling us to validate our main finding in an independent 
cohort. Finally, all samples were from one institute and 
handled by one dedicated technician to preclude variability 
in centre or in lab handling.
In conclusion, we showed that breast cancers for which 
gene expression data were successfully obtained were asso-
ciated with a higher grade and with lymph node metastasis, 
due to the selection of samples with a high tumor percentage 
and good quality RNA. These tumors have, on average, a 
more aggressive phenotype and a relatively poor progno-
sis. In general, when interpreting test results, it is important 
to realize that patient populations for which GE profiles 
are used, often differ substantially from the ones in which 
they were originally developed, particularly when using a 
development cohort consisting of frozen tumor tissue and a 
test cohort consisting of FFPE samples. At this point, it is 
uncertain what the impact might be on treatment decisions 
in the clinic.
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Fig. 2  Kaplan–Meier curves of recurrence-free survival. Kaplan–Meier curves of recurrence-free survival to compare patients with and without 
gene expression profiles, stratified by subtype. GE denoted gene expression
Table 4  Patient characteristics in the validation dataset, split for gene 
expression status
GE denoted gene expression, IDC invasive ductal carcinoma, ILC 
invasive lobular carcinoma, ER oestrogen receptor, HER2 ERBB2
Bold p-values denote p-values statitically significant at a 0.05 cut-off
n = 585
No GE data 
available 
(n = 158)
GE data avail-
able (n = 427)
p value
Age  < 50 yr 86 (54%) 251 (59%) 0.34
 ≥ 50 yr 72 (46%) 176 (41%)
 Unknown 0 0
Histology  IDC 125 (79%) 345 (81%) 0.11
 ILC 12 (7%) 47 (11%)
 Rest 21 (13%) 35 (8%)
 Unknown 0 0
Subtype  Luminal 121 (77%) 312 (73%) 0.49
 Her2 19 (12%) 48 (11%)
 Triple nega-
tive
18 (11%) 65 (15%)
 Unknown 0 2
ER  ER Neg 23 (15%) 85 (20%) 0.14
 ER Pos 135 (85%) 342 (80%)
 Unknown 0 0
Her2  Her2 Neg 119 (75%) 358 (88%) 0.55
 Her2 Pos 19 (14%) 48 (1%)
 unknown 20 21
Grade  Grade 1 & 2 120 (76%) 291 (68%) 0.05
 Grade 3 37 (24%) 136 (32%)
 Unknown 1 0
T-stage  T1/T2 158 (100%) 426 (99%) 0.54
 T3/T4 0 1 (1%)
 Unknown 0 0
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